AbbVie lowers 2026 adjusted EPS guidance after Q3 expense
AbbVie announced that its 2026 adjusted diluted earnings per share (EPS) guidance is now $13.76 to $13.96, down from the prior range of $13.87 to $14.07. The revision reflects $216 million of acquired IPR&D and milestones expenses recorded in the third quarter, which reduces the EPS outlook by $0.11 per share. The company also updated its Q3 2026 adjusted EPS guidance to $3.73‑$3.77 per share.
Why it matters
The company says the lower guidance reflects the impact of the $216 million expense and signals reduced profitability for the year, which may affect investor expectations and valuation. Analysts will need to adjust their models to incorporate the revised EPS range.
Key facts
- 12026 adjusted diluted EPS guidance is $13.76‑$13.96 per share. stocktitan.net
- 22026 adjusted diluted EPS guidance was previously $13.87‑$14.07 per share. quiverquant.com
- 3Q3 2026 adjusted diluted EPS guidance is $3.73‑$3.77 per share. stocktitan.net
- 4AbbVie recorded $216 million of acquired IPR&D and milestones expense in Q3 2026. quiverquant.com
- 5The $216 million expense reduces adjusted EPS guidance by $0.11 per share. stocktitan.net
- 6Full‑year 2026 acquired IPR&D and milestones expense included in guidance totals $1.251 billion. quiverquant.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.